Navigation Links
Butrans® (Buprenorphine) Transdermal System CIII Pivotal Phase 3 Data Published in the Journal of Pain and Symptom Management
Date:10/26/2011

STAMFORD, Conn., Oct. 26, 2011 /PRNewswire/ -- A pivotal Phase 3 study of Butrans® (buprenorphine) Transdermal System CIII in opioid-naive patients with moderate-to-severe chronic low back pain demonstrated significantly lower "average pain over the last 24 hours" scores compared to placebo at the end of a 12-week, randomized, double-blind phase, in a study published in the online version of the September issue of the Journal of Pain and Symptom Management.

"These data are important in understanding the role of Butrans for opioid-naive patients with moderate-to-severe chronic pain requiring a continuous, around-the-clock opioid analgesic for an extended period of time," said Deborah Steiner, MD, MS, medical director at Purdue Pharma L.P.

The Butrans Transdermal System, approved by the U.S. Food and Drug Administration (FDA) in June 2010, is indicated for the management of moderate-to-severe chronic pain in patients requiring a continuous, around-the-clock opioid analgesic for an extended period of time.  Butrans is the first transdermal system approved in the United States that delivers continuous release of the active ingredient, buprenorphine, for seven days.

Butrans is a Schedule III opioid prescription medication and can be abused in a manner similar to other opioid agonists, legal or illicit.  Working with the FDA, Purdue Pharma L.P. has developed a Risk Evaluation and Mitigation Strategy (REMS) for Butrans that includes a Medication Guide, Elements to Assure Safe Use, such as a healthcare provider training guide, and a timetable for submitting assessments of the REMS.  This information is available at www.Butransrems.com.

Butrans is contraindicated in patients who have significant respiratory depression, severe bronchial asthma, who have or are suspected o
'/>"/>

SOURCE Purdue Pharma L.P.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain
2. Purdue Pharma L.P. to Present Data From Clinical Program for Butrans™ (buprenorphine) Transdermal System CIII at PAINWeek® 2010
3. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
4. Phosphagenics to Conduct a Phase 1 Transdermal Oxycodone Clinical Trial
5. Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinsons Disease
6. Rotigotine Transdermal System Shows Significant Symptom Reduction and Tolerability in Patients with Restless Legs Syndrome
7. Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
8. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
9. New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months
10. Echo Therapeutics Initiates Clinical Study of Its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
11. Echo Therapeutics Announces Publication of Positive Clinical Data for its Symphony Transdermal Continuous Glucose Monitoring System in Journal of Diabetes Science and Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 25, 2014  CVS Caremark Corporation (NYSE: ... Tuesday, August 5, 2014, at 8:30 a.m. (EDT) with ... financial results. An audio webcast of the ... Relations portion of the CVS Caremark website for all ... . This webcast will be archived and available on ...
(Date:7/25/2014)... -- Solanbridge Group Inc (OTC: SLNX) is pleased to announce ... and the Letter of Intent issued on July 11, ... Agreement. Charles R. Shirley , Managing ... Mr. David Pecoraro and Buzznbrewz.com join SLNX,s ... sector and developed a tremendous network of contacts who ...
(Date:7/25/2014)...  AMETEK, Inc. (NYSE: AME ) today ... as Vice President and General Manager, Engineered Medical Components, ... "I am pleased that Kurt has joined ... experience, especially in the medical device industry, and we ... growth and success of our medical components businesses," commented ...
Breaking Medicine Technology:Solanbridge Group Inc Announces Acquisition of Buzznbrewz.com 2AMETEK Names Kurtis L. Goos, Vice President & General Manager, Engineered Medical Components 2
... Intensive Blood Sugar Control Are, Not Statistically Significant but Show Favorable Trend ... ... Events, SAN FRANCISCO, June 8 Findings from the Veterans,Affairs Diabetes ... diabetes patients were,released today at the 68th Scientific Sessions of the American ...
... the ... Diabetes Association, SAN FRANCISCO, June 7 Amylin Pharmaceuticals,Inc. (Nasdaq: ... and Alkermes, Inc.,(Nasdaq: ALKS ) announced results from a 30-week ... formulation of,exenatide, to BYETTA(R) (exenatide) injection. Type 2 diabetes patients,treated with ...
Cached Medicine Technology:Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA(R) 2Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA(R) 3Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA(R) 4Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight 2Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight 3Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight 4Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight 5Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight 6Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight 7Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight 8
(Date:7/25/2014)... 25, 2014 As reported by People Magazine ... After Jersey Shore and Getting Sober (7/15), one of ... Shore, has spoken out to the public about his personal ... show, The Situation admits that moving on with his life ... drugs, and other drugs in 2012 and even spent some ...
(Date:7/25/2014)... News) -- The human brain can preserve oxygen to ... study finds. Although dehydration significantly reduces blood ... that the brain compensates by increasing the amount of ... has helped us understand a lot more about how ... conditions," study first author Steven Trangmar, a researcher at ...
(Date:7/25/2014)... July 25, 2014 Art of Facial Surgery ... to those in Toronto who are looking for minor touch-ups ... study done by the American Academy of Facial Plastic and ... interest in facial plastic surgery showed a surprising increase between ... 10 percent, while hair transplants increased by 7 percent and ...
(Date:7/25/2014)... 2014 A new study of participants in ... are published today in Cancer , found evidence that ... who had an abnormal finding on a lung cancer screening ... life than did those who were screened and found to ... to the researchers. “We expected that participants with an abnormal ...
(Date:7/25/2014)... 2014(BRONX, NY)A study involving nearly 27,000 older adults on ... criteria for pre-dementia based on a simple test that ... cognitive complaints. People who tested positive for pre-dementia were ... 12 years. The study, led by scientists at ... and Montefiore Medical Center , was published online ...
Breaking Medicine News(10 mins):Health News:'The Situation' Celebrates 8 Months of Sobriety 2Health News:'The Situation' Celebrates 8 Months of Sobriety 3Health News:Human Brain Has Coping Mechanism for Dehydration 2Health News:Art of Facial Surgery Responds to Demand for Facial Plastic Surgery Increase Due to the Popularity of Selfies 2Health News:Art of Facial Surgery Responds to Demand for Facial Plastic Surgery Increase Due to the Popularity of Selfies 3Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 2Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 3Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 4Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 5Health News:Slow walking speed and memory complaints can predict dementia 2Health News:Slow walking speed and memory complaints can predict dementia 3Health News:Slow walking speed and memory complaints can predict dementia 4
... on sodas, other sweet beverages may work better than eating ... When it comes to losing weight, cutting back on the ... important. , So say researchers who found that cutting back ... per day -- accounted for nearly two-and-a-half pounds of ...
... In a press conference today, Colgate and,the Hispanic ... Salud,Bucal: Un Mundo de Sonrisas Saludables (Oral Health Month: ... commitment to quality oral care among the,Hispanic community. , ... lack of familiarity accessing oral,healthcare services, among other factors, ...
... (Nasdaq: MEDQ ), a leading provider of ... final judgment approving settlement and dismissing the consolidated medical ... of the results of the internal review of its ... about its workforce, and throughout this litigation the Company ...
... Company Reports Earnings per Share of 9 cents ... April 2 Allscripts-Misys Healthcare Solutions, Inc. (Allscripts) ... and nine months ended February 28, 2009. (Logo: ... months ended February 28, 2009 include results of ...
... of a Big Brothers Big Sisters of America ... women mentors, revealed that strong emotional support and ... was a dominant theme coupled with the development ... , Unlike previous mentoring studies, this one explicitly ...
... April 2 Varian Medical Systems (NYSE: ... a mid-year review for investors from noon through 2 p.m. ... hotel located at 1 Avenue De Lafayette. Management presentations ... year 2009, strategic initiatives, and growth opportunities in markets for ...
Cached Medicine News:Health News:Fewer Sugary Drinks Key to Weight Loss 2Health News:Fewer Sugary Drinks Key to Weight Loss 3Health News:Colgate and the Hispanic Dental Association Proclaim April El Mes de la Salud Bucal to Promote Oral Health Fundamentals Among Hispanics 2Health News:Colgate and the Hispanic Dental Association Proclaim April El Mes de la Salud Bucal to Promote Oral Health Fundamentals Among Hispanics 3Health News:MedQuist Announces Entry of Final Judgment Approving Settlement and Dismissing Medical Transcriptionist Class Action 2Health News:MedQuist Announces Entry of Final Judgment Approving Settlement and Dismissing Medical Transcriptionist Class Action 3Health News:Allscripts Reports Fiscal 2009 Third Quarter Results 2Health News:Allscripts Reports Fiscal 2009 Third Quarter Results 3Health News:Allscripts Reports Fiscal 2009 Third Quarter Results 4Health News:Allscripts Reports Fiscal 2009 Third Quarter Results 5Health News:Allscripts Reports Fiscal 2009 Third Quarter Results 6Health News:Allscripts Reports Fiscal 2009 Third Quarter Results 7Health News:Allscripts Reports Fiscal 2009 Third Quarter Results 8Health News:Allscripts Reports Fiscal 2009 Third Quarter Results 9Health News:Allscripts Reports Fiscal 2009 Third Quarter Results 10Health News:Allscripts Reports Fiscal 2009 Third Quarter Results 11Health News:Allscripts Reports Fiscal 2009 Third Quarter Results 12Health News:Allscripts Reports Fiscal 2009 Third Quarter Results 13Health News:Allscripts Reports Fiscal 2009 Third Quarter Results 14Health News:Gaining new insights into mentoring programs for adolescent girls 2Health News:Gaining new insights into mentoring programs for adolescent girls 3Health News:Varian Medical Systems Schedules Mid-Year Review With Investors in Boston 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: